Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Solo Brands Inc DTC

Solo Brands, Inc. develops and produces ingenious lifestyle products that market and deliver through its direct-to-consumer (DTC) platform and wholesale partnerships. The Company operates six outdoor brands: Solo Stove, Oru Kayak, Inc. (Oru), International Surf Ventures, Inc. (ISLE), Chubbies, Inc. (Chubbies), Sconberg, LLC (TerraFlame) and IcyBreeze Cooling, LLC (IcyBreeze). Its brands develop... see more

NYSE:DTC - Post Discussion

Solo Brands Inc > Defence Therapeutics Granted CNRI-H from the Canadian Nuclea
View:
Post by whytestocks on Jul 24, 2024 3:32am

Defence Therapeutics Granted CNRI-H from the Canadian Nuclea

Just In: $DTC Defence Therapeutics Granted CNRI-H from the Canadian Nuclear Laboratories to Accelerate the Development of Its Radio-Immuno-Conjugates ProgramVancouver, British Columbia--(Newsfile Corp. - July 24, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company developing novel immune-oncology vaccines and drug delivery technologies, is pleased to announce that i...DTC - Defence Therapeutics Granted CNRI-H from the Canadian Nuclear Laboratories to Accelerate the Development of Its Radio-Immuno-Conjugates Program
Be the first to comment on this post
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities